Clinical Trials

EMA Fast-Tracks Approval for Adapted COVID-19 Variant Vaccines
Management & Regulatory EMA Fast-Tracks Approval for Adapted COVID-19 Variant Vaccines

EMA Fast-Tracks Approval for Adapted COVID-19 Variant Vaccines In an agile response to the rapidly mutating SARS-CoV-2 virus, the European Medicines Agency (EMA) has set forth new guidance to expedite the regulatory approval of COVID-19 vaccines modified to combat emerging variants. This move

Can AI Revolutionize Cancer Drug Development?
Research & Development Can AI Revolutionize Cancer Drug Development?

In a pivotal step toward enhancing cancer treatment, Oregon Therapeutics has joined forces with Lantern Pharma to escalate the development of a pivotal cancer drug, XCE853. This collaborative venture showcases AI's potential to transform medical innovations and potentially bring groundbreaking

Moderna and OpenAI Forge AI Path in Vaccine Development
Management & Regulatory Moderna and OpenAI Forge AI Path in Vaccine Development

In a groundbreaking initiative, Moderna has joined forces with AI powerhouse OpenAI to revolutionize vaccine development through artificial intelligence. This move signifies a fusion of Moderna's medical prowess with OpenAI's advanced AI technology. Together, they seek to transform the way vaccines

Revolutionary Naked mRNA Vaccine Aims to Transform Immunizations
Research & Development Revolutionary Naked mRNA Vaccine Aims to Transform Immunizations

In the ongoing battle against contagious diseases, researchers at the Innovation Center of NanoMedicine's Uchida Laboratory have made a significant breakthrough with the creation of a "naked mRNA" vaccine. This innovative technology harnesses messenger RNA to invoke an immune response without the

Is Lantern Pharma's LP-300 a New Hope for NSCLC Patients?
Management & Regulatory Is Lantern Pharma's LP-300 a New Hope for NSCLC Patients?

Lantern Pharma's LP-300 signals a significant advancement in the fight against non-small cell lung cancer (NSCLC), particularly in never-smokers—a group seeing elevated incidence rates, notably in East Asia. This promising therapeutic option stands out as NSCLC treatments often overlook the unique

Is ALLO-316 the Future of Kidney Cancer Treatment?
Research & Development Is ALLO-316 the Future of Kidney Cancer Treatment?

In the fight against kidney cancer, ALLO-316, created by Allogene Therapeutics, stands out in the vanguard with its CAR T-cell therapy. This breakthrough offers new hope against renal cell carcinoma (RCC), a type notorious for its defiance against traditional treatments. As ALLO-316 progresses

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later